New drug REGN22044 tested in people for the first time
NCT ID NCT07526116
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is the first time REGN22044 is given to humans. It will enroll 64 healthy adults to check for side effects, measure drug levels in the blood, and see if the body makes antibodies against it. The goal is to gather safety and dosing information, not to treat any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?